| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.03 |